SCHEMBL17294763

SCHEMBL17294763

CN1CCC(NC(=O)C(O)c2ccccc2)CC1

nearest known ligand 0.69

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CCR1 P32246 1/20 0.48
SSTR4 P31391 1/20 0.48
P2RX4 Q99571 1/20 0.48
CHRM3 P20309 3/20 0.48
GRM7 Q14831 2/20 0.48
KDM4E B2RXH2 1/20 0.47
GAA P10253 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17294624 1.00 TSHR (0.50) TSHRCCR1SSTR4P2RX4CHRM3
SCHEMBL17294744 1.00 TSHR (0.50) TSHRCCR1SSTR4P2RX4CHRM3
SCHEMBL17294636 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294696 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294637 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294635 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294773 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294771 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL17294633 0.83 HTT (0.50) TSHRCCR1CHRM3GAANPSR1
SCHEMBL4620504 0.83 TSHR (0.60) TSHRKDM4EGAANPSR1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148518-B1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PRIVATE LTD (IN) 2022-11-30 EP claimed
CN-106659697-B Compounds as antituberculosis agents 斯菲叶尔制药私有公司 2022-03-29 CN claimed
US-10207993-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2019-02-19 US claimed
US-10100012-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2018-10-16 US claimed
US-20170334851-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2017-11-23 US claimed
US-20170183305-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2017-06-29 US claimed
EP-3148518-A2 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS Sphaera Pharma Pvt. Ltd. (IN) 2017-04-05 EP claimed
WO-2015181837-A2 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2015-12-03 WO claimed
EP-3148518-B1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PRIVATE LTD (IN) 2022-11-30 EP disclosed
CN-106659697-B Compounds as antituberculosis agents 斯菲叶尔制药私有公司 2022-03-29 CN disclosed
US-10207993-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2019-02-19 US disclosed
US-10100012-B2 Compounds as anti-tubercular agents SPHAERA PHARMA PVT. LTD. (IN) 2018-10-16 US disclosed
US-20170334851-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2017-11-23 US disclosed
US-20170183305-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2017-06-29 US disclosed
EP-3148518-A2 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS Sphaera Pharma Pvt. Ltd. (IN) 2017-04-05 EP disclosed
WO-2015181837-A2 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS SPHAERA PHARMA PVT. LTD. (IN) 2015-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10100012-B2 Compounds as anti-tubercular agents FNTB, G6PD, PGGT1B TSHR 4086/4885CCR1 1514/4885SSTR4 4394/4885
US-10207993-B2 Compounds as anti-tubercular agents FNTB, G6PD, PGGT1B TSHR 4086/4885CCR1 1514/4885SSTR4 4394/4885
US-20170334851-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS FNTB, PGGT1B, GGPS1 TSHR 4067/4885CCR1 1727/4885SSTR4 4650/4885
US-20170183305-A1 NOVEL COMPOUNDS AS ANTI-TUBERCULAR AGENTS FNTB, PGGT1B, GGPS1 TSHR 4067/4885CCR1 1727/4885SSTR4 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.